Skip to main content

European Bank for induced pluripotent Stem Cells


Start Date
End Date
Total Funding
€ 34 327 858
Funding Programme
European Countries Involved
Induced pluripotent stem cells (iPSC) are the cornerstone of many regenerative medicine projects, and offer researchers a powerful new approach to model and study a range of diseases. The European Bank for Induced Pluripotent Stem Cells (EBiSC) was established to provide researchers across academia and the pharmaceutical industry with disease-relevant, quality-controlled, research-grade iPSC lines, data and cell services, and to promote the wider use of iPSCs with the ultimate goal of improving health. EBiSC began setting up the banking infrastructure in 2014 and distributing cell lines from March 2016 onwards. Today, there are more than 800 iPSC lines in the EBiSC catalogue, covering neurodegenerative diseases, diabetes, eye and heart diseases, muscular dystrophies, and lines from healthy control donors.
Project partners
Janssen Pharmaceutica Nv
The University Of Edinburgh
Roslin Cells Ltd.
Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V
Genome Research Limited
Edelweiss Connect Gmbh
European Molecular Biology Laboratory
Charite - Universitaetsmedizin Berlin
University Of Newcastle Upon Tyne
Klinikum Der Universitaet Zu Koeln
Gottfried Wilhelm Leibniz Universitaet Hannover
Koninklijke Nederlandse Akademie Van Wetenschappen - Knaw
European Screeningport Gmbh
Ucl Elizabeth Garrett Anderson Institute For Women’S Health
Department Of Health
Bioneer A/S
Universitatsklinikum Bonn
Definigen Ltd
Instituto De Salud Carlos Iii
Astrazeneca Ab
H. Lundbeck As
Novo Nordisk A/S
Ucb Pharma Sa
Pfizer Limited
Ucb Biopharma Srl
Bayer Aktiengesellschaft
Roslin Cell Sciences Ltd
Eli Lilly And Company Limited
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).